Chitosan nanoparticles-based therapeutics for multidrug‐resistantbacterial infections

Today, the number of effective antibiotics for the treatment of infectious diseases is rapidly declining, which has a serious impact on human health. The pharmaceutical and biomedical sections are facing the ongoing increase in multidrug-resistant (MDR) human pathogens. MDR bacterial infections lead to considerable growth in morbidity, fatality and cost of long-term treatments. Nanomaterial therapy is an instrument that promises to fight sever-to-treat bacterial infections that can bypass existing mechanisms associated with acquired drug resistance. Recently, chitosan has received a lot of attention for its role in inhibiting bacteria and drug delivery. Because chitosan contains many functional bioactive groups that promote chemical reactions and transformations. Also It has numerous advantages, such as nontoxicity, biocompatibility, and biodegradability. Multifunctional Chitosan nanoparticles represent a new hope for the treatment of various pathogenic bacteria that cause antibiotic resistance. This study discusses the antibacterial activity of chitosan nanoparticles against of the MDR bacteria. Although the in vitro antimicrobial activity of chitosan and its derivatives has recently been studied, in vivo activity has been insufficiently accumulated. This study will focus more on recent studies of in vivo antimicrobial activity of chitosan as a carrier of antibacterial agents to treat MDR.

Keywords:

multidrug-resistant (MDR) , Nanomaterial , antibacterial agent , chitosan nanoparticles